Liposomes as protein carriers in immunology

Journal of Liposome Research

Volumn 14, Issue 3-4, 2004, Pages 175-189

  Leserman, Lee ^a  

^a CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

Author keywords

Adaptive immune response; Antigen presentation; Dendritic cells; Lymphocytes; Vaccine

Indexed keywords

ANTIGEN; CARRIER PROTEIN; IMMUNOLOGICAL ADJUVANT; LIPOSOME; TOLL LIKE RECEPTOR; TUMOR VACCINE;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG UPTAKE; HUMAN; IMMUNE SYSTEM; IMMUNOTHERAPY; LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR EVOLUTION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS; B-LYMPHOCYTES; DENDRITIC CELLS; DRUG CARRIERS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNITY, NATURAL; LIPOSOMES; MEMBRANE GLYCOPROTEINS; NEOPLASMS; PROTEINS; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 11144220545     PISSN: 08982104     EISSN: None     Source Type: Journal    
DOI: 10.1081/LPR-200039198     Document Type: Review

References (87)

1. Allison A, Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974; 252:252.
2. Alving CR. Liposomes as carriers of antigens and adjuvants. Immunol Meth 1991; 140:1-13.
3. Wassef N, Alving C, Richards R. Liposomes as carriers for vaccines. Immunomethods 1994; 4:217-222.
4. Leserman L, Barois N. Major histocompatibility complex class II molecules, liposomes and antigen presentation. In: Lasic DD, Papahadjopoulos D, eds. Medical Applications of Liposomes. Amsterdam: Elsevier, 1998:25-45.
5. Medzhitov R, Janeway CA Jr. An ancient system of host defense. Curr Opin Immunol 1998; 10:12-15.
6. Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA. Phylogenetic perspectives in innate immunity. Science 1999; 284:1313-1318.
7. Fischer A, Malissen B. Natural and engineered disorders of lymphocyte development. Science 1998; 280:237-243.
8. Braud VM, Allan DS, McMichael AJ. Functions of nonclassical MHC and non-MHC-encoded class I molecules. Curr Opin Immunol 1999; 11:100-108.
9. Jameson J, Ugarte K, Chen N, Yachi P, Fuchs E, Boismenu R, Havran WL. A role for skin gamma delta T cells in wound repair. Science 2002; 296:747-749.
10. Yasuda T, Dancey GF, Kinsky SC. Immunogenic properties of liposomal model membranes in mice. J Immunol 1977; 119:1863-1867.
11. Steinman R. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9:271-296.
12. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004; 4:211-222.
13. Henri S, Vremec D, Kamath A, Waithman J, Williams S, Benoist C, Burnham K, Saeland S, Handman E, Shortman K. The dendritic cell populations of mouse lymph nodes. J Immunol 2001; 167:741-748.
14. Inaba K, Steinman RM. Protein-specific helper T-lymphocyte formation initiated by dendritic cells. Science 1985; 229:475-479.
15. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393:480-483.
16. Zinkernagel RM, Doherty PC. Immunological surveillance against self components by sensitized T lymphocytes in lymphocytic choriomeningitis. Nature 1974; 251:547.
17. Finberg R, Mescher M, Burakoff SJ. The induction of virus-specific cytotoxic T lymphocytes with solubilized viral and membrane proteins. J Exp Med 1978; 148:1620-1627.
18. Curman B, Ostberg L, Peterson PA. Incorporation of murine MHC antigens into liposomes and their effect in the secondary mixed lymphocyte reaction. Nature 1978; 272:545-547.
19. Littman DR, Cullen SE, Schwartz BD. Insertion of Ia and H-2 alloantigens into model membranes. Proc Natl Acad Sci U S A 1979; 76:902-906.
20. Engelhard VH, Kaufman JF, Strominger JL, Burakoff SJ. Specificity of mouse cytotoxic T lymphocytes stimulated with either HLA-A and -B or HLA-DR antigens reconstituted into phospholipid vesicles. J Exp Med 1980; 152:54s-64s.
21. Handa K, Herrmann S. Defining cytolytic T lymphocyte recognition of chemically modified self. I. Response to trinitrophenyl-H-2Kk. J Immunol 1985; 135:1564-1572.
22. Watts T, Brian A, Kappler J, Marrack P, McConnell H. Antigen presentation by supported planar membranes containing affinity-purified I-Ad. Proc Natl Acad Sci U S A 1984; 81:7564-7568.
23. Dudda JC, Martin SF. Tissue targeting of T cells by DCs and microenvironments. Trends Immunol 2004; 25:417-421.
24. Gregoriadis G, McCormack B, Obrenovic M, Saffie R, Zadi B, Perrie Y. Vaccine entrapment in liposomes. Methods 1999; 19:156-162.
25. Villadangos JA, Bryant RA, Deussing J, Driessen C, Lennon-Dumenil AM, Riese RJ, Roth W, Saftig P, Shi GP, Chapman HA, Peters C, Ploegh HL. Proteases involved in MHC class II antigen presentation. Immunol Rev 1999; 172:109-120.
26. Trombetta ES, Ebersold M, Garrett W, Pypaert M, Mellman I. Activation of lysosomal function during dendritic cell maturation. Science 2003; 299:1400-1403.
27. Storni T, Ruedl C, Renner WA, Bachmann MF. Innate immunity together with duration of antigen persistence regulate effector T cell induction. J Immunol 2003; 171:795-801.
28. Askew D, Chu RS, Krieg AM, Harding CV. CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. J Immunol 2000; 165:6889-6895.
29. Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000; 404:770-774.
30. Nair S, Zhou F, Reddy R, Huang L, Rouse BT. Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. J Exp Med 1992; 175:609-612.
31. Arkema A, Huckriede A, Schoen P, Wilschut J, Daemen T. Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. Vaccine 2000; 18:1327-1333.
32. Collins DS, Findlay K, Harding CV. Processing of exogenous liposome-encapsulated antigens in vivo generates class I MHC-restricted T cell responses. J Immunol 1992; 148:3336-3341.
33. Machy P, Serre K, Leserman L. Class I-restricted presentation of exogenous antigen acquired by Fcγ receptor-mediated endocytosis is regulated in dendritic cells. Eur J Immunol 2000; 30:848-857.
34. Machy P, Serre K, Baillet M, Leserman L. Induction of MHC-class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains. J Immunol 2002; 168:1172-1180.
35. Schumacher R, Adamina M, Zurbriggen R, Bolli M, Padovan E, Zajac P, Heberer M, Spagnoli GC. Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation. Vaccine 2004; 22:715-724.
36. Apostolou I, Von Boehmer H. In vivo instruction of suppressor commitment in naive T cells. J Exp Med 2004; 199:1401-1408.
37. Morelli AE, Larregina AT, Shufesky WJ, Zahorchak AF, Logar AJ, Papworth GD, Wang Z, Watkins SC, Falo LD Jr, Thomson AW. Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production. Blood 2003; 101:611-620.
38. Szebeni J. The interaction of liposomes with the complement system. Crit Rev Ther Drug Carr Syst 1998; 15:57-88.
39. van Broekhoven CL, Parish CR, Demangel C, Britton WJ, Altin JG. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res 2004; 64:4357-4365.
40. Krishnan L, Sad S, Patel GB, Sprott GD. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge. Cancer Res 2003; 63:2526-2534.
41. Medzhitov R, Janeway C Jr. Innate immune recognition: mechanisms and pathways. Immunol Rev 2000; 173:89-97.
42. Akira S. Mammalian toll-like receptors. Curr Opin Immunol 2003; 15:5-11.
43. Barton GM, Medzhitov R. Toll-like receptor signaling pathways. Science 2003; 300:1524-1525.
44. Pulendran B. Modulating vaccine responses with dendritic cells and toll-like receptors. Immunol Rev 2004; 199:227-250.
45. Alexopoulou L, Thomas V, Schnare M, Lobet Y, Anguita J, Schoen RT, Medzhitov R, Fikrig E, Flavell RA. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat Med 2002; 8:878-884.
46. Alving C, Banerji B, Shiba T, Kotani S, Clements J, Richards R. Liposomes as vehicles for vaccines. Prog Clin Biol Res 1980; 47:339-355.
47. Alving C. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiology 1993; 187:430-446.
48. Li WM, Dragowska WH, Bally MB, Schutze-Redelmeier MP. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 2003; 21:3319-3329.
49. Milhaud PG, Machy P, Colote S, Lebleu B, Leserman L. Free and liposome-encapsulated double-stranded RNAs as inducers of interferon, interleukin-6, and cellular toxicity. J Interf Res 1991; 11:261-265.
50. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383:787-793.
51. Allison A, Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974; 252:252.
52. Gregoriadis G, Allison AC. Entrapment of proteins in liposomes prevents allergic reactions in pre-immunized mice. FEBS Lett 1974; 45:71-74.
53. Volsky DJ, Loyter A. An efficient method for reassembly of fusogenic Sendai virus envelopes after solubilization of intact virions with Triton X-100. FEBS Lett 1978; 92:190-194.
54. Morein B, Helenius A, Simons K, Schirrmacher V. Virus spike protein complexes and virosomes as effective subunit vaccines. Adv Exp Med Biol 1979; 114:811-816.
55. Trudel M, Ravaoarinoro M, Payment P. Reconstitution of rubella hemagglutinin on liposomes. Can J Microbiol 1980; 26:899-904.
56. Lawman MJP, Naylor PT, Huang L, Courtney RJ, Rouse BT. Cell-mediated immunity to Herpes simplex virus: induction of cytotoxic T lymphocyte responses by viral antigens incorporated into liposomes. J Immunol 1981; 126:304-308.
57. Greenstein J, Herrmann S, Sunshine G, Burakoff S. The mechanism of antigen presentation by dendritic cells and splenic adherent cells in the induction of an allogeneic cytotoxic T-lymphocyte response to H-2Kk liposomes. Cell Immunol 1986; 100:389-399.
58. Watts T, McConnell H. High-affinity fluorescent peptide binding to I-Ad in lipid membranes. Proc Natl Acad Sci U S A 1986; 83:9660-9664.
59. Gregoriadis G, Davis D, Davies A. Liposomes as immunological adjuvants: antigen incorporation studies. Vaccine 1987; 5:145-151.
60. Garcon N, Gregoriadis G, Taylor M, Summerfield J. Mannose-mediated targeted immunoadjuvant action of liposomes. Immunology 1988; 64:743-745.
61. Harding CV, Collins DS, Slot JW, Geuze HJ, Unanue ER. Liposome-encapsulated antigens are processed in lysosomes, recycled and presented to T cells. Cell 1991; 64:393-401.
62. Fries L, Gordon D, Richards R, Egan J, Hollingdale M, Gross M, Silverman C, Alving C. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci U S A 1992; 89:358-362.
63. Gluck R. Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens. Vaccine 1992; 10:915-919.
64. Glück R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ Jr. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994; 344:160-163.
65. Heit A, Maurer T, Hochrein H, Bauer S, Huster KM, Busch DH, Wagner H. Cutting edge: toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for coss-priming of CD8 T cells. J Immunol 2003; 170:2802-2805.
66. Matsumoto M, Funami K, Tanabe M, Oshiumi H, Shingai M, Seto Y, Yamamoto A, Seya T. Subcellular localization of toll-like receptor 3 in human dendritic cells. J Immunol 2003; 171:3154-3162.
67. Vabulas RM, Pircher H, Lipford GB, Hacker H, Wagner H. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses. J Immunol 2000; 164:2372-2378.
68. Chikh GG, Kong S, Bally MB, Meunier J-C, Schutze-Redelmeier M-PM. Efficient delivery of Antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J Immunol 2001; 167:6255-6462.
69. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, Zinkernagel R, Aguzzi A. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004; 10:187-192.
70. Loisel S, Le Gall C, Doucet L, Ferec C, Floch V. Contribution of plasmid DNA to hepatotoxicity after systemic administration of lipoplexes. Hum Gene Ther 2001; 12:685-696.
71. Storni T, Ruedl C, Schwarz K, Schwendener RA, Renner WA, Bachmann MF. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 2004; 172:1777-1785.
72. Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Immunol Today 2000; 21:447-455.
73. Underhill DM. Mini-review toll-like receptors: networking for success. Eur J Immunol 2003; 33:1767-1775.
74. Chonn A, Semple S, Cullis P. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem 1992; 267:18759-18765.
75. van Rooijen N. Antigen processing and presentation in vivo: the microenvironment as a critical factor. Immunol Today 1990; 11:436-439.
76. van Rooijen N. Liposomes as an in vivo tool to study and manipulate macrophage function. Res Immunol 1992; 143:177-178.
77. van Rooijen N. Macrophages as accessory cells in the in vivo humoral immune response: from processing of particulate antigens to regulation by suppression. Semin Immunol 1992; 4:237-245.
78. Nair S, Buiting A, Rouse R, Van Rooijen N, Huang L, Rouse B. Role of macrophages and dendritic cells in primary cytotoxic T lymphocyte responses. Int Immunol 1995; 7:679-688.
79. Leenen PJ, Radosevic K, Voerman JS, Salomon B, van Rooijen N, Klatzmann D, van Ewijk W. Heterogeneity of mouse spleen dendritic cells: in vivo phagocytic activity, expression of macrophage markers, and subpopulation turnover. J Immunol 1998; 160:2166-2173.
80. Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 1999; 11:753-761.
81. Serre K, Machy P, Grivel J-C, Jolly G, Brun N, Barbet J, Leserman L. Efficient presentation of multivalent antigens targeted to various cell surface molecules of dendritic cells and surface immunoglobulin of antigen-specific B cells. J Immunol 1998; 161:6059-6067.
82. Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol 2004; 16:143-150.
83. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFN- and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-1111.
84. Rangarajan A, Weinberg RA. Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev, Cancer 2003; 3:952-959.
85. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425:516-521.
86. Mohty M, Olive D, Gaugler B. Plasmacytoid DCs and cancer: a new role for an enigmatic cell. Trends Immunol 2004; 25:397-398.
87. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9:1269-1274.